Sermorelin: What to Expect, Week-by-Week First Month

What Is Sermorelin and How Does It Work?

Sermorelin is the biologically active N-terminal 29-amino-acid fragment of endogenous growth hormone-releasing hormone (GHRH 1-44). It binds GHRH receptors on pituitary somatotroph cells, triggering a pulse of GH secretion that mirrors the body's natural midnight surge. Because it works through the pituitary rather than bypassing it, GH output stays subject to normal negative-feedback control via somatostatin. That physiological brake is why IGF-1 overshoot is less likely with sermorelin than with exogenous recombinant human GH (rhGH) at equivalent therapeutic doses 1.

Mechanism Compared with Exogenous GH

Recombinant GH injects GH directly into the bloodstream, suppressing the pituitary's own output over time. Sermorelin, by contrast, preserves the hypothalamic-pituitary axis. The pituitary can still respond to somatostatin-mediated inhibition, so the risk of sustained supraphysiologic IGF-1 is lower. A 1996 Endocrine Society review of GHRH analogues noted that pulsatile GH release maintains a more favorable GH/IGF-1 ratio than continuous exogenous infusion 2.

Regulatory Background

The FDA approved Geref (sermorelin acetate for injection) in 1997 for pediatric GHD. The manufacturer voluntarily withdrew the NDA in 2008 due to commercial reasons, not safety concerns. Compounding pharmacies licensed under 503A continue to prepare sermorelin under individual prescriptions for clinicians treating adult GH insufficiency off-label 3.

The Clinical Evidence Base

Adult data for sermorelin specifically are limited compared with rhGH, so understanding the available evidence helps set realistic expectations.

Walker et al. Pediatrics 1990 (Anchor Trial)

Walker et al. Enrolled 60 children with confirmed GHD in a randomized controlled trial comparing sermorelin 30 mcg/kg/day subcutaneously against placebo over 6 months 1. Mean growth velocity in the sermorelin group increased from 3.4 cm/year at baseline to 8.1 cm/year at 6 months (P<0.001). IGF-1 rose significantly from baseline but remained within age-appropriate reference ranges throughout the study, demonstrating the pituitary's self-regulatory capacity.

Adult IGF-1 and Body Composition Data

A double-blind crossover trial published in the Journal of Clinical Endocrinology and Metabolism (Corpas et al. 1992, N=16 healthy elderly men) found that 2 weeks of continuous GHRH(1-29) infusion at 0.5 mcg/kg/hr raised IGF-1 by approximately 40% and 24-hour GH pulse amplitude by 72% compared with placebo 4. Lean mass increased modestly but significantly; fat mass trended downward without reaching statistical significance over that short window.

A separate 6-month trial (Vittone et al. 1997, N=21 older men) using nightly sermorelin 0.5 mcg/kg subcutaneously showed a statistically significant 1.6-kg increase in lean body mass and a 1.1-kg reduction in fat mass versus placebo 5. Sleep-stage architecture, specifically slow-wave sleep, improved by week 4 in the active arm.

What the Evidence Does Not Yet Show

No large randomized trial (N>200) has evaluated sermorelin in adults with confirmed GH insufficiency over 12 months or longer. The Endocrine Society's 2019 clinical practice guideline on adult GHD recommends rhGH as first-line replacement, noting that GHRH analogues lack sufficient long-term adult safety and efficacy data to earn a formal recommendation 6. Clinicians who prescribe sermorelin off-label do so in the context of these evidence gaps, relying on mechanism-of-action rationale and smaller trials.

Week-by-Week Breakdown: Month One

Most patients ask a straightforward question: what will I feel, and when? The timeline below reflects clinical observations from the published trials above plus the pharmacokinetics of sermorelin (plasma half-life approximately 10 to 20 minutes after subcutaneous injection, with GH pulse peaking roughly 30 to 60 minutes post-dose) 7.

Week 1 (Days 1 to 7): Baseline Establishment and First Signals

Sermorelin has a plasma half-life of roughly 10 to 20 minutes. GH pulses peak within 30 to 60 minutes of the injection, then clear rapidly. Patients should not expect sustained elevated GH levels the way one might with a long-acting peptide.

What patients typically report:

• Vivid dreams or deeper sleep by nights 3 to 5. This aligns with the known relationship between GH secretion and slow-wave sleep onset; GHRH itself has sleep-promoting effects independent of GH release 8.
• Mild injection-site redness or itching in approximately 16% of patients per the Geref prescribing data, usually resolving within 30 minutes 3.
• Transient flushing in some patients, lasting under 10 minutes post-injection.

What patients should not expect yet:

Body composition changes, strength gains, or measurable IGF-1 shifts are not present at one week. The pituitary needs repeated stimulation across multiple nights to recalibrate its GH secretory pattern.

Dosing note for week 1: Many prescribers start at 200 mcg nightly for the first two weeks to allow tolerability assessment before titrating to 300 to 500 mcg. Injections are given subcutaneously in the abdomen or thigh, 30 to 60 minutes after the last meal of the day to avoid the blunting effect of elevated insulin on GH release 9.

Week 2 (Days 8 to 14): Sleep Consolidation and Early Recovery

By the end of week 2, most patients on 200 to 300 mcg nightly report consistent improvements in sleep quality. The Vittone 1997 trial showed that slow-wave sleep improvements were statistically significant at the 4-week mark 5, and clinical experience suggests the trend begins earlier, around day 10 to 12.

Recovery and morning energy. Patients who train regularly may notice they feel less sore the morning after resistance workouts. GH itself promotes lipolysis and nitrogen retention. Because sermorelin's GH pulses now occur nightly with some consistency, amino-acid partitioning toward muscle repair may begin shifting modestly during this week.

Appetite changes. A subset of patients reports mildly increased appetite by week 2. GH can influence ghrelin signaling; this effect tends to normalize by week 4 to 6 as the system adapts 10.

Headache. Mild frontal headache within the first hour post-injection occurs in roughly 8 to 12% of users during week 1 to 2 and typically resolves without intervention. Persistent headache warrants clinical review to rule out elevated intracranial pressure, a known rare adverse effect of GH-axis stimulation 6.

Week 3 (Days 15 to 21): Functional Gains Begin

Week 3 is where patients who exercise consistently begin to notice functional differences. These are not dramatic. Think of a 5 to 10% subjective improvement in workout endurance or faster recovery between sessions rather than a visible physique change.

What the data suggest at this point: The Corpas 1992 study showed IGF-1 rising approximately 40% above baseline within 2 weeks of continuous GHRH(1-29) infusion 4. Nightly subcutaneous sermorelin produces a pulsatile, intermittent pattern rather than continuous infusion. IGF-1 rises more gradually, so the 40% figure is a ceiling reference rather than a week-3 expectation.

Skin texture and hydration. GH stimulates collagen synthesis and sebaceous gland activity. Some patients begin noticing slightly improved skin texture or hydration by week 3, though this is subjective and not quantified in controlled trials.

Libido. A subset of male patients reports modestly improved libido by week 3. This likely reflects improved sleep quality and overall vitality rather than a direct androgenic effect, since sermorelin has no androgen receptor activity 2.

Week 4 (Days 22 to 30): First Lab Check and Dose Optimization

Week 4 is the first meaningful clinical milestone. Obtain an IGF-1 level drawn fasting in the morning, at least 24 hours after the most recent injection, to get a valid steady-state trough reading. This mirrors the monitoring approach recommended in the Endocrine Society's GHD guideline for titrating rhGH, adapted for sermorelin's shorter time-to-steady-state 6.

Target IGF-1 at 4 weeks: Most clinicians aim for an IGF-1 in the upper quartile of the age- and sex-adjusted reference range. For a 40-year-old male, that typically means 175 to 230 ng/mL. Values above 250 ng/mL should trigger a dose reduction or temporary hold. Values below 150 ng/mL with no clinical response may support a cautious titration to 400 to 500 mcg nightly.

Body composition at 4 weeks: Do not expect scale changes yet. The Vittone 1997 trial showed a 1.6-kg lean mass gain and 1.1-kg fat loss over 6 months 5, which averages roughly 270 g lean gain and 180 g fat loss per month. These shifts are below the threshold of most consumer scales and certainly below DXA resolution at 4 weeks.

What good response looks like at day 30:

• IGF-1 has risen from baseline (typically 15 to 35% above pre-treatment value)
• Sleep quality rated subjectively improved, with fewer nighttime awakenings
• Energy levels on waking improved relative to baseline
• No new injection-site reactions or systemic adverse effects

Dosing Protocol: Standard First-Month Framework

The table below reflects typical prescribing patterns derived from compounding pharmacy prescriptions and the trial dosing used in Vittone 1997 and Corpas 1992.

| Week | Dose | Timing | Primary Goal | |------|------|---------|--------------| | 1 to 2 | 200 mcg nightly | 30 to 60 min post-dinner, bedtime | Tolerability, sleep onset | | 3 to 4 | 200 to 300 mcg nightly | Same | IGF-1 baseline rise, sleep consolidation | | 5 to 8 | 300 to 400 mcg nightly | Same | Body-composition shift begins | | 9 to 12 | 300 to 500 mcg nightly | Same | Measurable lean mass, IGF-1 in target range |

Dose is adjusted based on the week-4 IGF-1 result and clinical symptoms. Patients with a BMI above 30 may require higher doses because adiposity blunts GH secretion; conversely, lean patients may respond at lower doses 11.

Monitoring Schedule

Proper monitoring keeps IGF-1 within safe ranges and documents clinical response.

Baseline Labs (Before First Injection)

• IGF-1 (fasting, morning)
• Fasting glucose and HbA1c (GH raises insulin resistance transiently)
• Fasting lipid panel
• Complete metabolic panel
• If clinically indicated: pituitary MRI to rule out mass lesion before stimulating GH axis

The FDA label for Geref warned that sermorelin should not be initiated in patients with active pituitary tumors 3. This caution applies equally to compounded formulations.

4-Week Labs

• IGF-1 (fasting, morning, 24 hours post-injection)
• Fasting glucose

12-Week Labs

• IGF-1
• Fasting glucose and HbA1c
• Repeat lipid panel
• DXA scan if body composition tracking is a clinical goal

The Endocrine Society guideline states: "We recommend monitoring IGF-1 levels every 1 to 2 months until a stable dose is achieved, then every 6 months thereafter" in the context of GH replacement therapy 6. Sermorelin prescribers adapt this framework to the 4-week and 12-week checkpoints given the shorter stimulation timeline.

Common Side Effects and How to Manage Them

Injection-Site Reactions

Redness, swelling, or discomfort at the injection site occurs in approximately 16% of patients per the original Geref label data 3. Rotating sites daily across four quadrants of the abdomen reduces this significantly. Most reactions resolve within 30 minutes.

Flushing and Headache

Transient flushing and mild headache within the first 30 to 60 minutes post-injection are the most commonly reported systemic effects. Both typically diminish after the first 2 weeks as the body adapts to nightly GH pulses. Persistent or severe headache requires clinical evaluation.

Glucose Metabolism

GH promotes insulin resistance. Patients with pre-diabetes (HbA1c 5.7 to 6.4%) should have fasting glucose monitored at 4 and 12 weeks. In the Corpas 1992 trial, no significant change in fasting glucose was observed over 2 weeks at the doses studied, but longer-term data with higher doses remain limited 4.

Rare Adverse Effects

Antibody formation to sermorelin was detected in a small percentage of pediatric patients during the original clinical development program. The clinical significance in adults is unclear. Hypothyroidism may be unmasked or worsened because GH stimulates T4-to-T3 conversion, reducing reverse T3; patients on thyroid medication should recheck thyroid function at 12 weeks 12.

Who Is a Candidate for Sermorelin?

The Endocrine Society defines adult GHD as a peak GH response below 3 mcg/L on a validated stimulation test (insulin tolerance test or glucagon stimulation test) in a patient with clinical features of GHD 6. Formal diagnosis requires stimulation testing; sermorelin is prescribed off-label for patients with subthreshold GH secretion who do not meet the criteria for rhGH but have symptomatic GH insufficiency.

Patients Likely to Respond

• Adults aged 35 to 65 with confirmed low-normal IGF-1 (below the 25th percentile for age and sex)
• Patients reporting poor slow-wave sleep, prolonged recovery from exercise, or central adiposity without other metabolic explanation
• Patients who want to preserve pituitary axis integrity rather than bypass it with exogenous GH

Patients Who Should Not Use Sermorelin

• Active malignancy (GH axis stimulation may promote tumor growth) 6
• Known pituitary tumor or history of pituitary radiation without clearance from endocrinology
• Pregnancy or breastfeeding (no safety data)
• Patients with uncontrolled type 2 diabetes (HbA1c above 8.5%) given the insulin-resistance effect

Practical Injection Technique

Subcutaneous injection into the periumbilical abdomen produces consistent absorption. Inject at a 45-degree angle using a 29-gauge, 0.5-inch insulin syringe. Reconstituted sermorelin (typically 6 mg lyophilized powder per vial, reconstituted with 6 mL bacteriostatic water to yield 1,000 mcg/mL) should be refrigerated and used within 30 days of reconstitution. Never freeze the reconstituted solution.

Timing relative to meals matters. GH release is blunted by elevated insulin, so dosing at least 90 minutes after the last carbohydrate-containing meal, or immediately before bed after a protein-only snack, maximizes the pituitary response 9.

Sermorelin vs. Other GHRH/GHS Options

| Agent | Mechanism | Half-life | GH Pulse Pattern | Evidence Level | |-------|-----------|-----------|-----------------|----------------| | Sermorelin | GHRH receptor agonist | 10 to 20 min | Pulsatile, physiologic | Moderate (RCTs, N<100) | | CJC-1295 (without DAC) | GHRH analogue | ~30 min | Pulsatile | Low (no published RCTs in adults) | | Ipamorelin | Ghrelin receptor agonist | ~2 hours | Pulsatile | Low (animal + small human data) | | rhGH (somatropin) | Direct GH replacement | 2 to 4 hours | Supraphysiologic bolus | High (multiple RCTs, FDA approved) |

Sermorelin sits in a middle ground: more evidence than newer peptides, less than rhGH, and a preserved pituitary axis as a distinguishing feature.